Glutamatergic neurotransmission as molecular target of new anticonvulsants

Current Topics in Medicinal Chemistry

Volumn 12, Issue 9, 2012, Pages 971-993

  Gitto, Rosaria ^a   de Luca, Laura ^a   de Grazia, Sara ^a   Chimirri, Alba ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

AMPA; Anticonvulsants; Epilepsy; Glutamate; Glutamate transporters; iGluR; mGluR

Indexed keywords

1,2,3,6,7,8 HEXAHYDRO 3 (HYDROXYMINO) N,N 7 TRIMETHYL 2 OXOBENZO[2,1 B:3,4 C]DIPYRROLE 5 SULFONAMIDE; 1,4,7,8,9,10 HEXAHYDRO 9 METHYL 6 NITROPYRIDO[3,4 F]QUINOXALINE 2,3 DIONE; 10 AMINO 10 METHYL 8 METHYLUREIDO 4,5 DIHYDRO 4 OXO 10H IMIDAZO[1,2 A] INDENO[1,2 E]PYRAZINE; 3 (HYDROXYIMINO) N,N DIMETHYL 2 OXO 2,3,6,7,8,9 HEXAHYDRO 1H BENZO[G]INDOLE 5 SULFONAMIDE; 5 METHYL 1 NICOTINOYL 2 PYRAZOLINE; 6 (1 IMIDAZOLYL) 7 NITRO 2,3 QUINOXALINEDIONE; 6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; 6,7 DINITRO 2,3 QUINOXALINEDIONE; 8 METHYLUREIDOIMIDAZOINDENOPYRAZINE 2 CARBIXYLIC ACID; 9 CARBOXYMETHYL 4 OXO 5H,10H IMIDAZO[1,2 A]INDENO[1,2 E]PYRAZIN 2 PHOSPHONIC ACID; 9 CARBOXYMETHYLIMIDAZO[1,2 A]INDENO[1,2 E]PYRAZIN 4 ONE 2 CARBOXYLIC ACID; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; BECAMPANEL; CARBAMAZEPINE; CLOBAZAM; FANAPANEL; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; GLUTAMINE; IONOTROPIC RECEPTOR; KAINIC ACID RECEPTOR; METABOTROPIC RECEPTOR; MS 153; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NS 229; NS 257; POSTSYNAPTIC RECEPTOR; RPR 117824; RPR 119990; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZONAMPANEL; ZONISAMIDE;

AMINO ACID SYNTHESIS; ANTICONVULSANT ACTIVITY; BIOSYNTHESIS; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TARGETING; EPILEPSY; EXCITOTOXICITY; GLUTAMATERGIC TRANSMISSION; HUMAN; LEARNING; MEMORY; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PRESYNAPTIC NERVE; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 84860462329     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612800229242     Document Type: Review

References (194)

1. Perucca, E.; Tomson, T. The pharmacological treatment of epilepsy in adults. Lancet Neurol., 2011, 10(5), 446-456.
2. Sasa, M. A new frontier in epilepsy: novel antiepileptogenic drugs. J. Pharmacol. Sci., 2006, 100(5), 487-494.
3. Moult, P.R. Neuronal glutamate and GABAA receptor function in health and disease. Biochem. Soc. Trans., 2009, 37(Pt 6), 1317-1322.
4. Meldrum, B.S.; Rogawski, M.A. Molecular targets for antiepileptic drug development. Neurotherapeutics, 2007, 4(1), 18-61.
5. Rogawski, M.A. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res., 2006, 69(3), 273-294.
6. Tang, F.R.; Bradford, H.F.; Ling, E.A. Metabotropic glutamate receptors in the control of neuronal activity and as targets for development of anti-epileptogenic drugs. Curr. Med. Chem., 2009, 16(17), 2189-2204.
7. Bowie, D. Ionotropic glutamate receptors & CNS disorders. CNS Neurol. Disord-DR, 2008, 7(2), 129-143.
8. Traynelis, S.F.; Wollmuth, L.P.; McBain, C.J.; Menniti, F.S.; Vance, K.M.; Ogden, K.K.; Hansen, K.B.; Yuan, H.; Myers, S.J.; Dingledine, R. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol. Rev., 2010, 62(3), 405-496.
9. Byrnes, K.R.; Loane, D.J.; Faden, A.I. Metabotropic glutamate receptors as targets for multipotential treatment of neurological disorders. Neurotherapeutics, 2009, 6(1), 94-107.
10. Shigeri, Y.; Seal, R.P.; Shimamoto, K. Molecular pharmacology of glutamate transporters, EAATs and VGLUTs. Brain Res. Brain Res. Rev., 2004, 45(3), 250-265.
11. Pedretti, A.; De Luca, L.; Sciarrillo, C.; Vistoli, G. Fragmental modeling of human glutamate transporter EAAT1 and analysis of its binding modes by docking and pharmacophore mapping. Chem Med Chem., 2008, 3(1), 79-90.
12. Nieoullon, A.; Canolle, B.; Masmejean, F.; Guillet, B.; Pisano, P.; Lortet, S. The neuronal excitatory amino acid transporter EAAC1/EAAT3: does it represent a major actor at the brain excitatory synapse? J. Neurochem., 2006, 98(4), 1007-1018.
13. Mim, C.; Balani, P.; Rauen, T.; Grewer, C. The glutamate transporter subtypes EAAT4 and EAATs 1-3 transport glutamate with dramatically different kinetics and voltage dependence but share a common uptake mechanism. J. Gen. Physiol., 2005, 126(6), 571-589.
14. Melone, M.; Bellesi, M.; Ducati, A.; Iacoangeli, M.; Conti, F. Cellular and Synaptic Localization of EAAT2a in Human Cerebral Cortex. Front. Neuroanat., 2011, 4, 151.
15. Kaczor, A.A.; Matosiuk, D. Molecular structure of ionotropic glutamate receptors. Curr. Med. Chem., 2010, 17(24), 2608-2635.
16. IUPHAR database http://www.iuphar-db.org/
17. Collingridge, G.L.; Olsen, R.; Peters, J.A.; Spedding, M. Ligand gated ion channels. Neuropharmacology, 2009, 56(1), 1.
18. Mayer, M.L. Structure and mechanism of glutamate receptor ion channel assembly, activation and modulation. Curr. Opin. Neurobiol., 2011, 21(2), 283-290.
19. Gitto, R.; Barreca, M.L.; De Luca, L.; Chimirri, A. New trends in the development of AMPA receptor antagonists. Expert Opin. Ther. Patents, 2004, 14(8), 1199-1213.
20. Catarzi, D.; Colotta, V.; Varano, F. Competitive AMPA receptor antagonists. Med. Res. Rev., 2007, 27(2), 239-278.
21. De Sarro, G.; Gitto, R.; Russo, E.; Ibbadu, G.F.; Barreca, M.L.; De Luca, L.; Chimirri, A. AMPA receptor antagonists as potential anticonvulsant drugs. Curr. Top. Med. Chem., 2005, 5(1), 31-42.
22. Mony, L.; Kew, J.N.; Gunthorpe, M.J.; Paoletti, P. Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential. Br. J. Pharmacol., 2009, 157(8), 1301-1317.
23. Beinat, C.; Banister, S.; Moussa, I.; Reynolds, A.J.; McErlean, C.S.; Kassiou, M. Insights into structure-activity relationships and CNS therapeutic applications of NR2B selective antagonists. Curr. Med. Chem., 2010, 17(34), 4166-4190.
24. Sobolevsky, A.I.; Rosconi, M.P.; Gouaux, E. X-ray structure, symmetry and mechanism of an AMPA-subtype glutamate receptor. Nature, 2009, 462(7274), 745-756.
25. Paoletti, P. Molecular basis of NMDA receptor functional diversity. Eur. J. Neurosci., 2011, 33(8), 1351-1365.
26. Paoletti, P.; Neyton, J. NMDA receptor subunits: function and pharmacology. Curr. Opin. Pharmacol., 2007, 7(1), 39-47.
27. Jane, D.E.; Lodge, D.; Collingridge, G.L. Kainate receptors: pharmacology, function and therapeutic potential. Neuropharmacology, 2009, 56(1), 90-113.
28. Vincent, P.; Mulle, C. Kainate receptors in epilepsy and excitotoxicity. Neuroscience, 2009, 158(1), 309-323.
29. Nicoletti, F.; Bockaert, J.; Collingridge, G.L.; Conn, P.J.; Ferraguti, F.; Schoepp, D.D.; Wroblewski, J.T.; Pin, J.P. Metabotropic glutamate receptors: From the workbench to the bedside. Neuropharmacology, 2011. 60(7-8), 1017-1041.
30. Caraci, F.; Molinaro, G.; Battaglia, G.; Giuffrida, M.L.; Riozzi, B.; Traficante, A.; Bruno, V.; Cannella, M.; Merlo, S.; Wang, X.; Heinz, B.A.; Nisenbaum, E.S.; Britton, T.C.; Drago, F.; Sortino, M.A.; Copani, A.; Nicoletti, F. Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotective. Mol. Pharmacol., 2011, 79(3), 618-626.
31. Szydlowska, K.; Tymianski, M. Calcium, ischemia and excitotoxicity. Cell calcium, 2010, 47(2), 122-129.
32. Muir, K.W. Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr. Opin. Pharmacol., 2006, 6(1), 53-60.
33. Lau, A.; Tymianski, M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Archiv: Eur. J. Physiol., 2010, 460(2), 525-542.
34. Beart, P.M.; O'Shea, R.D. Transporters for L-glutamate: an update on their molecular pharmacology and pathological involvement. Br. J. Pharmacol., 2007, 150(1), 5-17.
35. Campbell, S.L.; Hablitz, J.J. Decreased glutamate transport enhances excitability in a rat model of cortical dysplasia. Neurobiol. Dis., 2008, 32(2), 254-261.
36. Shimada, F.; Shiga, Y.; Morikawa, M.; Kawazura, H.; Morikawa, O.; Matsuoka, T.; Nishizaki, T.; Saito, N. The neuroprotective agent MS-153 stimulates glutamate uptake. Eur. J. Pharmacol., 1999, 386(2-3), 263-270.
37. Ganel, R.; Ho, T.; Maragakis, N.J.; Jackson, M.; Steiner, J.P.; Rothstein, J.D. Selective up-regulation of the glial Na+-dependent glutamate transporter GLT1 by a neuroimmunophilin ligand results in neuroprotection. Neurobiol. Dis., 2006, 21(3), 556-567.
38. Beart, P.M.; O'Shea, R.D. Transporters for L-glutamate: an update on their molecular pharmacology and pathological involvement. Br. J. Pharmacol., 2007, 150(1), 5-17.
39. Jahn, R. VGLUTs--potential targets for the treatment of seizures? Neuron, 2010, 68(1), 6-8.
40. Dutuit, M.; Touret, M.; Szymocha, R.; Nehlig, A.; Belin, M.F.; Didier-Bazes, M. Decreased expression of glutamate transporters in genetic absence epilepsy rats before seizure occurrence. J. Neurochem., 2002, 80(6), 1029-1038.
41. Touret, M.; Parrot, S.; Denoroy, L.; Belin, M.F.; Didier-Bazes, M. Glutamatergic alterations in the cortex of genetic absence epilepsy rats. BMC Neurosci., 2007, 8, 69.
42. Mattes, H.; Carcache, D.; Kalkman, H.O.; Koller, M. alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside. J. Med. Chem., 2010, 53(15), 5367-5382.
43. Rogawski, M.A. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr., 2011, 11(2), 56-63.
44. Palmer, C.L.; Cotton, L.; Henley, J.M. The molecular pharmacology and cell biology of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. Pharmacol. Rev., 2005, 57(2), 253-277.
45. Armstrong, N.; Gouaux, E. Mechanisms for activation and antagonism of an AMPA-sensitive glutamate receptor: crystal structures of the GluR2 ligand binding core. Neuron, 2000, 28(1), 165-181.
46. Hogner, A.; Greenwood, J.R.; Liljefors, T.; Lunn, M.L.; Egebjerg, J.; Larsen, I.K.; Gouaux, E.; Kastrup, J.S. Competitive antagonism of AMPA receptors by ligands of different classes: crystal structure of ATPO bound to the GluR2 ligand-binding core, in comparison with DNQX. J. Med. Chem., 2003, 46(2), 214-221.
47. Cruz, L.A.; Estebanez-Perpina, E.; Pfaff, S.; Borngraeber, S.; Bao, N.; Blethrow, J.; Fletterick, R.J.; England, P.M. 6-Azido-7-nitro-1,4-dihydroquinoxaline-2,3-dione (ANQX) forms an irreversible bond to the active site of the GluR2 AMPA receptor. J. Med. Chem., 2008, 51(18), 5856-5860.
48. Kasper, C.; Pickering, D.S.; Mirza, O.; Olsen, L.; Kristensen, A.S.; Greenwood, J.R.; Liljefors, T.; Schousboe, A.; Watjen, F.; Gajhede, M.; Sigurskjold, B.W.; Kastrup, J.S. The structure of a mixed GluR2 ligand-binding core dimer. J. Mol. Biol., 2006, 357, (4), 1184-1201.
49. Ahmed, A.H.; Thompson, M.D.; Fenwick, M.K.; Romero, B.; Loh, A.P.; Jane, D.E.; Sondermann, H.; Oswald, R.E. Mechanisms of antagonism of the GluR2 AMPA receptor: structure and dynamics of the complex of two willardiine antagonists with the glutamate binding domain. Biochemistry, 2009, 48(18), 3894-3903.
50. Ahmed, A.H.; Wang, Q.; Sondermann, H.; Oswald, R.E. Structure of the S1S2 glutamate binding domain of GLuR3. Proteins, 2009, 75(3), 628-637.
51. Kubo, M.; Ito, E. Structural dynamics of an ionotropic glutamate receptor. Proteins, 2004, 56(3), 411-419.
52. Ahmed, A.H.; Loh, A.P.; Jane, D.E.; Oswald, R.E. Dynamics of the S1S2 glutamate binding domain of GluR2 measured using 19F NMR spectroscopy. J. Biol. Chem., 2007, 282(17), 12773-12784.
53. Valentine, E.R.; Palmer, A.G., 3rd. Microsecond-to-millisecond conformational dynamics demarcate the GluR2 glutamate receptor bound to agonists glutamate, quisqualate, and AMPA. Biochemistry, 2005, 44(9), 3410-3417.
54. De Luca, L.; Macchiarulo, A.; Costantino, G.; Barreca, M.L.; Gitto, R.; Chimirri, A.; Pellicciari, R. Binding modes of noncompetitive AMPA antagonists: a computational approach. Farmaco, 2003, 58(2), 107-113.
55. Chapman, A.G.; Smith, S.E.; Meldrum, B.S. The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466, in mice. Epilepsy Res., 1991, 9(2), 92-96.
56. Bigge, C.F.; Malone, T.C.; Boxer, P.A.; Nelson, C.B.; Ortwine, D.F.; Schelkun, R.M.; Retz, D.M.; Lescosky, L.J.; Borosky, S.A.; Vartanian, M.G. Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]-quinoxaline-2,3-dione and related quinoxalinediones: characterization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D-aspartate) receptor and anticonvulsant activity. J. Med. Chem., 1995, 38(19), 3720-3740.
57. Turski, L.; Schneider, H.H.; Neuhaus, R.; McDonald, F.; Jones, G.H.; Lofberg, B.; Schweinfurth, H.; Huth, A.; Kruger, M.; Ottow, E. Phosphonate quinoxalinedione AMPA antagonists. Restor. Neurol. Neurosci., 2000, 17(1), 45-59.
58. Takahashi, M.; Ni, J.W.; Kawasaki-Yatsugi, S.; Toya, T.; Yatsugi, S.I.; Shimizu-Sasamata, M.; Koshiya, K.; Shishikura, J.I.; Sakamoto, S.; Yamaguchi, T. YM872, a novel selective alphaamino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, reduces brain damage after permanent focal cerebral ischemia in cats. J. Pharmacol. Exp. Ther., 1998, 284(2), 467-473.
59. Auberson, Y.P.; Acklin, P.; Bischoff, S.; Moretti, R.; Ofner, S.; Schmutz, M.; Veenstra, S.J. N-phosphonoalkyl-5-aminomethylquinoxaline-2,3-diones: in vivo active AMPA and NMDA(glycine) antagonists. Bioorg. Med. Chem. Lett., 1999, 9(2), 249-254.
60. Catarzi, D.; Lenzi, O.; Colotta, V.; Varano, F.; Poli, D.; Filacchioni, G.; Lingenhohl, K.; Ofner, S. Pharmacological characterization of some selected 4,5-dihydro-4-oxo-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylates and 3-hydroxyquinazoline-2,4-diones as (S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)-propionic acid receptor antagonists. Chem. Pharm. Bull., 2010, 58(7), 908-911.
61. Cordi, A.A.; Desos, P.; Ruano, E.; Al-Badri, H.; Fugier, C.; Chapman, A.G.; Meldrum, B.S.; Thomas, J.Y.; Roger, A.; Lestage, P. Novel quinolinone-phosphonic acid AMPA antagonists devoid of nephrotoxicity. Farmaco, 2002, 57(10), 787-802.
62. Desos, P.; Lepagnol, J.M.; Morain, P.; Lestage, P.; Cordi, A.A. Structure-activity relationships in a series of 2(1H)-quinolones bearing different acidic function in the 3-position: 6,7-dichloro-2(1H)-oxoquinoline-3-phosphonic acid, a new potent and selective AMPA/kainate antagonist with neuroprotective properties. J. Med. Chem., 1996, 39(1), 197-206.
63. Mignani, S.; Bohme, G.A.; Birraux, G.; Boireau, A.; Jimonet, P.; Damour, D.; Genevois-Borella, A.; Debono, M.W.; Pratt, J.; Vuilhorgne, M.; Wahl, F.; Stutzmann, J.M. 9-Carboxymethyl-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one-2-carbocylic acid (RPR117824): selective anticonvulsive and neuroprotective AMPA antagonist. Bioorg. Med. Chem., 2002, 10(5), 1627-1637.
64. Canton, T.; Bohme, G.A.; Boireau, A.; Bordier, F.; Mignani, S.; Jimonet, P.; Jahn, G.; Alavijeh, M.; Stygall, J.; Roberts, S.; Brealey, C.; Vuilhorgne, M.; Debono, M.W.; Le Guern, S.; Laville, M.; Briet, D.; Roux, M.; Stutzmann, J.M.; Pratt, J. RPR 119990, a novel alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist: synthesis, pharmacological properties, and activity in an animal model of amyotrophic lateral sclerosis. J. Pharmacol. Exp. Ther. 2001, 299(1), 314-322.
65. Jimonet, P.; Bohme, G.A.; Bouquerel, J.; Boireau, A.; Damour, D.; Debono, M.W.; Genevois-Borella, A.; Hardy, J.C.; Hubert, P.; Manfre, F.; Nemecek, P.; Pratt, J.; Randle, J.C.; Ribeill, Y.; Stutzmann, J.M.; Vuilhorgne, M.; Mignani, S. Bioisosteres of 9-carboxymethyl-4-oxo-imidazo[1,2-a]indeno-[1,2-e]pyrazin-2-carboxylic acid derivatives. Progress towards selective, potent in vivo AMPA antagonists with longer durations of action. Bioorg. Med. Chem. Lett., 2001, 11(2), 127-132.
66. Jimonet, P.; Cheve, M.; Bohme, G.A.; Boireau, A.; Damour, D.; Debono, M.W.; Genevois-Borella, A.; Imperato, A.; Pratt, J.; Randle, J.C.; Ribeill, Y.; Stutzmann, J.M.; Vuilhorgne, M.; Mignani, S. 8-Methylureido-10-amino-10-methyl-imidazo[1,2-a]indeno[1,2-e] pyrazine-4-ones: highly in vivo potent and selective AMPA receptor antagonists. Bioorg. Med. Chem., 2000, 8(8), 2211-2217.
67. Stutzmann, J.M.; Bohme, G.A.; Boireau, A.; Damour, D.; Debono, M.W.; Genevois-Borella, A.; Imperato, A.; Jimonet, P.; Pratt, J.; Randle, J.C.; Ribeill, Y.; Vuilhorgne, M.; Mignani, S. 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with in vivo activity. Bioorg. Med. Chem. Lett., 2000, 10, (10), 1133-1137.
68. Watjen, F.; Bigge, C.F.; Jensen, L.H.; Boxer, P.A.; Lescosky, L.J.; Nielsen, E.O.; Malone, T.C.; Campbell, G.W.; Coughenour, L.L.; Rock, D.M.; Drejer, J.; Marcoux, F.W. Ns-257 (1,2,3,6,7,8-Hexahydro-3(Hydroxyimino)-N,N,7-Trimethyl-2-Oxobenzo[2,1-B-3,4-C']Dipyrrole-5-Sulfonamide) Is a Potent, Systemically Active Ampa Receptor Antagonist. Bioorg. Med. Chem. Lett., 1994, 4(2), 371-376.
69. Auberson, Y.P. Competitive AMPA antagonism: a novel mechanism for antiepileptic drugs? Drugs Fut., 2001, 26(5), 463-471.
70. Schoepp, D.D.; Lodge, D.; Bleakman, D.; Leander, J.D.; Tizzano, J.P.; Wright, R.A.; Palmer, A.J.; Salhoff, C.R.; Ornstein, P.L. In vitro and in vivo antagonism of AMPA receptor activation by (3S, 4aR, 6R, 8aR)-6-[2-(1(2)H-tetrazole-5-yl) ethyl] decahydroisoquinoline-3-carboxylic acid. Neuropharmacology, 1995, 34(9), 1159-1168.
71. Ornstein, P.L.; Arnold, M.B.; Augenstein, N.K.; Lodge, D.; Leander, J.D.; Schoepp, D.D. (3SR,4aRS,6RS,8aRS)-6-[2-(1Htetrazol-5-yl)ethyl]decahydroisoquinoline-3 -carboxylic acid: a structurally novel, systemically active, competitive AMPA receptor antagonist. J. Med. Chem., 1993, 36(14), 2046-2048.
72. Figueiredo, T.H.; Qashu, F.; Apland, J.P.; Aroniadou-Anderjaska, V.; Souza, A.P.; Braga, M.F. The GluK1 (GluR5) Kainate/{alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology. J. Pharmacol. Exp. Ther., 2011, 336(2), 303-312.
73. Solyom, S.; Tarnawa, I. Non-competitive AMPA antagonists of 2,3-benzodiazepine type. Curr. Pharmaceutic. Des., 2002, 8(10), 913-939.
74. Abraham, G.; Solyom, S.; Csuzdi, E.; Berzsenyi, P.; Ling, I.; Tarnawa, I.; Hamori, T.; Pallagi, I.; Horvath, K.; Andrasi, F.; Kapus, G.; Harsing, L.G., Jr.; Kiraly, I.; Patthy, M.; Horvath, G. New non competitive AMPA antagonists. Bioorg. Med. Chem., 2000, 8(8), 2127-2143.
75. Hamori, T.; Solyom, S.; Berzsenyi, P.; Andrasi, F.; Tarnawa, I. Structural analogues of some highly active non-competitive AMPA antagonists. Bioorg. Med. Chem. Lett., 2000, 10(9), 899-902.
76. Szenasi, G.; Vegh, M.; Szabo, G.; Kertesz, S.; Kapus, G.; Albert, M.; Greff, Z.; Ling, I.; Barkoczy, J.; Simig, G.; Spedding, M.; Harsing, L.G., Jr. 2,3-benzodiazepine-type AMPA receptor antagonists and their neuroprotective effects. Neurochemistry Int., 2008, 52(1-2), 166-183.
77. Howes, J.F.; Bell, C. Talampanel. Neurotherapeutics, 2007, 4(1), 126-129.
78. Bialer, M.; Johannessen, S.I.; Kupferberg, H.J.; Levy, R.H.; Perucca, E.; Tomson, T. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res., 2004, 61(1-3), 1-48.
79. Langan, Y.M.; Lucas, R.; Jewell, H.; Toublanc, N.; Schaefer, H.; Sander, J.W.; Patsalos, P.N. Talampanel, a new antiepileptic drug: single-and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. Epilepsia, 2003, 44(1), 46-53.
80. Vegh, M.G.; Kovacs, A.D.; Kovacs, G.; Szabo, G.; Tihanyi, K.; Harsing, L.G., Jr.; Levay, G. The new 2,3-benzodiazepine derivative EGIS-8332 inhibits AMPA/kainate ion channels and cell death. Neurochemistry Int., 2007, 50(3), 555-563.
81. Gigler, G.; Moricz, K.; Agoston, M.; Simo, A.; Albert, M.; Benedek, A.; Kapus, G.; Kertesz, S.; Vegh, M.; Barkoczy, J.; Marko, B.; Szabo, G.; Matucz, E.; Gacsalyi, I.; Levay, G.; Harsing, L.G., Jr.; Szenasi, G. Neuroprotective and anticonvulsant effects of EGIS-8332, a non-competitive AMPA receptor antagonist, in a range of animal models. Br. J. Pharmacol., 2007, 152(1), 151-160.
82. Chimirri, A.; De Sarro, G.; De Sarro, A.; Gitto, R.; Grasso, S.; Quartarone, S.; Zappala, M.; Giusti, P.; Libri, V.; Constanti, A.; Chapman, A.G. 1-Aryl-3,5-dihydro-4H-2,3-benzodiazepin-4-ones: novel AMPA receptor antagonists. J. Med. Chem., 1997, 40(8), 1258-1269.
83. De Sarro, G.; Rizzo, M.; Spagnolo, C.; Gitto, R.; De Sarro, A.; Scotto, G.; Zappala, M.; Chimirri, A. Anticonvulsant activity and plasma level of 2,3-benzodiazepin-4-ones (CFMs) in genetically epilepsy-prone rats. Pharmacol. Biochem. Behav., 1999, 63(4), 621-627.
84. Grasso, S.; De Sarro, G.; De Sarro, A.; Micale, N.; Polimeni, S.; Zappala, M.; Puia, G.; Baraldi, M.; De Micheli, C. Synthesis and anticonvulsant activity of novel and potent 1-aryl-7,8-methylenedioxy-1,2,3,5-tetrahydro-4H-2,3-benzodiazepin-4-ones. Bioorg. Med. Chem. Lett., 2001, 11(4), 463-466.
85. Chimirri, A.; De Sarro, G.; De Sarro, A.; Gitto, R.; Quartarone, S.; Zappala, M.; Constanti, A.; Libri, V. 3,5-Dihydro-4H-2,3-benzodiazepine-4-thiones: a new class of AMPA receptor antagonists. J. Med. Chem., 1998, 41(18), 3409-3416.
86. Zappala, M.; Gitto, R.; Bevacqua, F.; Quartarone, S.; Chimirri, A.; Rizzo, M.; De Sarro, G.; De Sarro, A. Synthesis and evaluation of pharmacological and pharmacokinetic properties of 11H-[1,2,4]triazolo[4,5-c][2,3]benzodiazepin-3(2H)-ones. J. Med. Chem., 2000, 43(25), 4834-4839.
87. Gitto, R.; Orlando, V.; Quartarone, S.; De Sarro, G.; De Sarro, A.; Russo, E.; Ferreri, G.; Chimirri, A. Synthesis and evaluation of pharmacological properties of novel annelated 2,3-benzodiazepine derivatives. J. Med. Chem., 2003, 46(17), 3758-3761.
88. Pelletier, J.C.; Hesson, D.P.; Jones, K.A.; Costa, A.M. Substituted 1,2-dihydrophthalazines: potent, selective, and noncompetitive inhibitors of the AMPA receptor. J. Med. Chem., 1996, 39(2), 343-346.
89. Pei, X.F.; Sturgess, M.A.; Valenzuela, C.F.; Maccecchini, M.L. Allosteric modulators of the AMPA receptor: novel 6-substituted dihydrophthalazines. Bioorg. Med. Chem. Lett., 1999, 9(4), 539-542.
90. Grasso, S.; De Sarro, G.; De Sarro, A.; Micale, N.; Zappala, M.; Puja, G.; Baraldi, M.; De Micheli, C. Synthesis and anticonvulsant activity of novel and potent 6,7-methylenedioxyphthalazin-1(2H)-ones. J. Med. Chem., 2000, 43(15), 2851-2859.
91. Menniti, F.S.; Chenard, B.L.; Collins, M.B.; Ducat, M.F.; Elliott, M.L.; Ewing, F.E.; Huang, J.I.; Kelly, K.A.; Lazzaro, J.T.; Pagnozzi, M.J.; Weeks, J.L.; Welch, W.M.; White, W.F. Characterization of the binding site for a novel class of noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonists. Mol. Pharmacol., 2000, 58(6), 1310-1317.
92. Menniti, F.S.; Buchan, A.M.; Chenard, B.L.; Critchett, D.J.; Ganong, A.H.; Guanowsky, V.; Seymour, P.A.; Welch, W.M. CP-465,022, a selective noncompetitive AMPA receptor antagonist, blocks AMPA receptors but is not neuroprotective in vivo. Stroke, 2003, 34(1), 171-176.
93. Chenard, B.L.; Welch, W.M.; Blake, J.F.; Butler, T.W.; Reinhold, A.; Ewing, F.E.; Menniti, F.S.; Pagnozzi, M.J. Quinazolin-4-one alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists: structure-activity relationship of the C-2 side chain tether. J. Med. Chem., 2001, 44(11), 1710-1717.
94. Mosley, C.A.; Acker, T.M.; Hansen, K.B.; Mullasseril, P.; Andersen, K.T.; Le, P.; Vellano, K.M.; Brauner-Osborne, H.; Liotta, D.C.; Traynelis, S.F. Quinazolin-4-one derivatives: A novel class of noncompetitive NR2C/D subunit-selective N-methyl-Daspartate receptor antagonists. J. Med. Chem., 2010, 53(15), 5476-5490.
95. Barreca, M.L.; Gitto, R.; Quartarone, S.; De Luca, L.; De Sarro, G.; Chimirri, A. Pharmacophore modeling as an efficient tool in the discovery of novel noncompetitive AMPA receptor antagonists. J. Chem. Inf. Comput. Sci., 2003, 43,(2), 651-655.
96. De Luca, L.; Gitto, R.; Barreca, M.L.; Caruso, R.; Quartarone, S.; Citraro, R.; De Sarro, G.; Chimirri, A. 3D pharmacophore models for 1,2,3,4-tetrahydroisoquinoline derivatives acting as anticonvulsant agents. Arch. Pharm. (Weinheim), 2006, 339(7), 388-400.
97. Rezessy, B.; Solyom, S. Advanced pharmacophore podel of non-Competitive AMPA antagonist 2,3-benzodiazepines. Lett. Drug Des. Disc., 2004, 1(3), 217-223.
98. Macchiarulo, A.; De Luca, L.; Costantino, G.; Barreca, M.L.; Gitto, R.; Pellicciari, R.; Chimirri, A. QSAR study of anticonvulsant negative allosteric modulators of the AMPA receptor. J. Med. Chem., 2004, 47(7), 1860-1863.
99. Gitto, R.; Barreca, M.L.; De Luca, L.; De Sarro, G.; Ferreri, G.; Quartarone, S.; Russo, E.; Constanti, A.; Chimirri, A. Discovery of a novel and highly potent noncompetitive AMPA receptor antagonist. J. Med. Chem., 2003, 46(1), 197-200.
100. Gitto, R.; Caruso, R.; Pagano, B.; De Luca, L.; Citraro, R.; Russo, E.; De Sarro, G.; Chimirri, A. Novel potent anticonvulsant agent containing a tetrahydroisoquinoline skeleton. J. Med. Chem., 2006, 49(18), 5618-5622.
101. Citraro, R.; Russo, E.; Gratteri, S.; Di Paola, E.D.; Ibbadu, G.F.; Curinga, C.; Gitto, R.; Chimirri, A.; Donato, G.; De Sarro, G. Effects of non-competitive AMPA receptor antagonists injected into some brain areas of WAG/Rij rats, an animal model of generalized absence epilepsy. Neuropharmacology, 2006, 51(6), 1058-1067.
102. Gitto, R.; Ficarra, R.; Stancanelli, R.; Guardo, M.; De Luca, L.; Barreca, M.L.; Pagano, B.; Rotondo, A.; Bruno, G.; Russo, E.; De Sarro, G.; Chimirri, A. Synthesis, resolution, stereochemistry, and molecular modeling of (R)-and (S)-2-acetyl-1-(4'-chlorophenyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinol ine AMPAR antagonists. Bioorg. Med. Chem., 2007, 15(16), 5417-5423.
103. Ohno, K.; Tsutsumi, R.; Matsumoto, N.; Yamashita, H.; Amada, Y.; Shishikura, J.; Yatsugi, H.I.; Okada, M.; Sakamoto, S.; Yamaguchi, T. Functional characterization of YM928, a novel moncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist. J. Pharmacol. Exp. Ther., 2003, 306(1), 66-72.
104. Wienrich, M.; Brenner, M.; Loscher, W.; Palluk, R.; Pieper, M.; Potschka, H.; Weiser, T. In vivo pharmacology of BIIR 561 CL, a novel combined antagonist of AMPA receptors and voltagedependent Na(+) channels. Br. J. Pharmacol., 2001, 133(6), 789-796.
105. Hanada, T.; Hashizume, Y.; Tokuhara, N.; Takenaka, O.; Kohmura, N.; Ogasawara, A.; Hatakeyama, S.; Ohgoh, M.; Ueno, M.; Nishizawa, Y. Perampanel: A novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia, 2011, 52(7), 1331-1340.
106. Gardoni, F.; Di Luca, M. New targets for pharmacological intervention in the glutamatergic synapse. Eur. J. Pharmacol., 2006, 545(1), 2-10.
107. Davies, J.; Francis, A.A.; Jones, A.W.; Watkins, J.C. 2-Amino-5-phosphonovalerate (2APV), a potent and selective antagonist of amino acid-induced and synaptic excitation. Neurosci. Lett., 1981, 21(1), 77-81.
108. Evans, R.H.; Francis, A.A.; Jones, A.W.; Smith, D.A.; Watkins, J.C. The effects of a series of omega-phosphonic alpha-carboxylic amino acids on electrically evoked and excitant amino acid-induced responses in isolated spinal cord preparations. Br. J. Pharmacol., 1982, 75(1), 65-75.
109. Fagg, G.E.; Olpe, H.R.; Schmutz, M.; Pozza, M.F.; van Riezen, H.; Bittiger, H.; Angst, C.; Brundish, D.; Allgeier, H.; Heckendorn, R. CGP 37849 and CGP 39551: novel competitive N-methyl-D aspartate receptor antagonists with potent oral anticonvulsant activity. Progr. Clin. Biol. Res., 1990, 361, 421-427.
110. Lehmann, J.; Hutchison, A.J.; McPherson, S.E.; Mondadori, C.; Schmutz, M.; Sinton, C.M.; Tsai, C.; Murphy, D.E.; Steel, D.J.; Williams, M. CGS 19755, a selective and competitive N-methyl-Daspartate-type excitatory amino acid receptor antagonist. J. Pharmacol.Exp.Ther., 1988, 246(1), 65-75.
111. Lowe, D.A.; Neijt, H.C.; Aebischer, B. D-CPP-ene (SDZ EAA 494), a potent and competitive N-methyl-D-aspartate (NMDA) antagonist: effect on spontaneous activity and NMDA-induced depolarizations in the rat neocortical slice preparation, compared with other CPP derivatives and MK-801. Neurosci. Lett., 1990, 113(3), 315-321.
112. Frizelle, P.A.; Chen, P.E.; Wyllie, D.J. Equilibrium constants for (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquino xalin-5-yl)-methyl]-phosphonic acid (NVPAAM077) acting at recombinant NR1/NR2A and NR1/NR2B Nmethyl-D-aspartate receptors: Implications for studies of synaptic transmission. Mol. Pharmacol., 2006, 70(3), 1022-1032.
113. Brandt, M.R.; Cummons, T.A.; Potestio, L.; Sukoff, S.J.; Rosenzweig-Lipson, S. Effects of the N-methyl-D-aspartate receptor antagonist perzinfotel [EAA-090; [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic acid] on chemically induced thermal hypersensitivity. J. Pharmacol. Exp. Ther., 2005, 313(3), 1379-1386.
114. Baudy, R.B.; Butera, J.A.; Abou-Gharbia, M.A.; Chen, H.; Harrison, B.; Jain, U.; Magolda, R.; Sze, J.Y.; Brandt, M.R.; Cummons, T.A.; Kowal, D.; Pangalos, M.N.; Zupan, B.; Hoffmann, M.; May, M.; Mugford, C.; Kennedy, J.; Childers, W.E., Jr. Prodrugs of perzinfotel with improved oral bioavailability. J. Med. Chem., 2009, 52(3), 771-778.
115. Costa, B.M.; Feng, B.; Tsintsadze, T.S.; Morley, R.M.; Irvine, M.W.; Tsintsadze, V.; Lozovaya, N.A.; Jane, D.E.; Monaghan, D.T. N-methyl-D-aspartate (NMDA) receptor NR2 subunit selectivity of a series of novel piperazine-2,3-dicarboxylate derivatives: preferential blockade of extrasynaptic NMDA receptors in the rat hippocampal CA3-CA1 synapse. J. Pharmacol. Exp. Ther., 2009, 331(2), 618-626.
116. Morley, R.M.; Tse, H.W.; Feng, B.; Miller, J.C.; Monaghan, D.T.; Jane, D.E. Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J. Med. Chem., 2005, 48(7), 2627-2637.
117. Feng, B.; Morley, R.M.; Jane, D.E.; Monaghan, D.T. The effect of competitive antagonist chain length on NMDA receptor subunit selectivity. Neuropharmacology, 2005, 48(3), 354-359.
118. Feng, B.; Tse, H.W.; Skifter, D.A.; Morley, R.; Jane, D.E.; Monaghan, D.T. Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl) piperazine-2,3-dicarboxylic acid. Br. J. Pharmacol., 2004, 141(3), 508-516.
119. Velisek, L.; Kusa, R.; Kulovana, M.; Mares, P. Excitatory amino acid antagonists and pentylenetetrazol-induced seizures during ontogenesis. I. The effects of 2-amino-7-phosphonoheptanoate. Life Sci., 1990, 46(19), 1349-1357.
120. Loscher, W.; Nolting, B.; Honack, D. Evaluation of CPP, a selective NMDA antagonist, in various rodent models of epilepsy. Comparison with other NMDA antagonists, and with diazepam and phenobarbital. Eur. J. Pharmacol., 1988, 152(1-2), 9-17.
121. Fagg, G.E.; Olpe, H.R.; Pozza, M.F.; Baud, J.; Steinmann, M.; Schmutz, M.; Portet, C.; Baumann, P.; Thedinga, K.; Bittiger, H. CGP 37849 and CGP 39551: novel and potent competitive Nmethyl-D-aspartate receptor antagonists with oral activity. Br. J. Pharmacol., 1990, 99(4), 791-797.
122. Grazioso, G.; Moretti, L.; Scapozza, L.; De Amici, M.; De Micheli, C. Development of a three-dimensional model for the N-methyl-Daspartate NR2A subunit. J. Med. Chem., 2005, 48(17), 5489-5494.
123. Kinarsky, L.; Feng, B.; Skifter, D.A.; Morley, R.M.; Sherman, S.; Jane, D.E.; Monaghan, D.T. Identification of subunit-and antagonist-specific amino acid residues in the N-Methyl-Daspartate receptor glutamate-binding pocket. J. Pharmacol. Exp. Ther., 2005, 313(3), 1066-1074.
124. Furukawa, H.; Singh, S.K.; Mancusso, R.; Gouaux, E. Subunit arrangement and function in NMDA receptors. Nature, 2005, 438(7065), 185-192.
125. Danysz, W.; Parsons, C.G. Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol. Rev., 1998, 50(4), 597-664.
126. Paoletti, P.; Neyton, J. NMDA receptor subunits: function and pharmacology. Curr. Opin. Pharmacol., 2007, 7(1), 39-47.
127. Inanobe, A.; Furukawa, H.; Gouaux, E. Mechanism of partial agonist action at the NR1 subunit of NMDA receptors. Neuron, 2005, 47(1), 71-84.
128. Furukawa, H.; Gouaux, E. Mechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand-binding core. The EMBO journal, 2003, 22(12), 2873-2885.
129. Chapman, A.G.; Durmuller, N.; Harrison, B.L.; Baron, B.M.; Parvez, N.; Meldrum, B.S. Anticonvulsant activity of a novel NMDA/glycine site antagonist, MDL 104,653, against kindled and sound-induced seizures. Eur. J. Pharmacol., 1995, 274(1-3), 83-88.
130. Wlaz, P.; Loscher, W. Weak anticonvulsant effects of two novel glycineB receptor antagonists in the amygdala-kindling model in rats. Eur. J. Pharmacol., 1998, 342(1), 39-46.
131. Bristow, L.J.; Hutson, P.H.; Kulagowski, J.J.; Leeson, P.D.; Matheson, S.; Murray, F.; Rathbone, D.; Saywell, K.L.; Thorn, L.; Watt, A.P.; Tricklebank, M.D. Anticonvulsant and behavioral profile of L-701,324, a potent, orally active antagonist at the glycine modulatory site on the N-methyl-D-aspartate receptor complex. J. Pharmacol. Exp. Ther., 1996, 279(2), 492-501.
132. Danysz, W.; Parsons, C.G.; Karcz-Kubicha, M.; Schwaier, A.; Popik, P.; Wedzony, K.; Lazarewicz, J.; Quack, G. GlycineB antagonists as potential therapeutic agents. Previous hopes and present reality. Amino acids, 1998, 14(1-3), 235-239.
133. Baron, B.M.; Cregge, R.J.; Farr, R.A.; Friedrich, D.; Gross, R.S.; Harrison, B.L.; Janowick, D.A.; Matthews, D.; McCloskey, T.C.; Meikrantz, S.; Nyce, P.L.; Vaz, R.; Metz, W.A. CoMFA, synthesis, and pharmacological evaluation of (E)-3-(2-carboxy-2-arylvinyl)-4,6-dichloro-1H-indole-2-carboxylic acids: 3-[2-(3-aminophenyl)-2-carboxyvinyl]-4,6-dichloro-1H-indole-2-carboxylic acid, a potent selective glycine-site NMDA receptor antagonist. J. Med. Chem., 2005, 48(4), 995-1018.
134. Di Fabio, R.; Capelli, A.M.; Conti, N.; Cugola, A.; Donati, D.; Feriani, A.; Gastaldi, P.; Gaviraghi, G.; Hewkin, C.T.; Micheli, F.; Missio, A.; Mugnaini, M.; Pecunioso, A.; Quaglia, A.M.; Ratti, E.; Rossi, L.; Tedesco, G.; Trist, D.G.; Reggiani, A. Substituted indole-2-carboxylates as in vivo potent antagonists acting as the strychnine-insensitive glycine binding site. J. Med. Chem., 1997, 40(6), 841-850.
135. Warner, D.S.; Martin, H.; Ludwig, P.; McAllister, A.; Keana, J.F.; Weber, E. In vivo models of cerebral ischemia: effects of parenterally administered NMDA receptor glycine site antagonists. J. Cereb. Blood Flow Metab., 1995, 15(2), 188-196.
136. Cai, S.X.; Huang, J.C.; Espitia, S.A.; Tran, M.; Ilyin, V.I.; Hawkinson, J.E.; Woodward, R.M.; Weber, E.; Keana, J.F. 5-(Noxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: novel, systemically active and broad spectrum antagonists for NMDA/glycine, AMPA, and kainate receptors. J. Med. Chem., 1997, 40(22), 3679-3686.
137. Ilyin, V.I.; Whittemore, E.R.; Guastella, J.; Weber, E.; Woodward, R.M. Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol. Mol. Pharmacol., 1996, 50(6), 1541-1550.
138. Ilyin, V.I.; Whittemore, E.R.; Tran, M.; Shen, K.Z.; Cai, S.X.; Kher, S.M.; Keana, J.F.; Weber, E.; Woodward, R.M. Pharmacology of ACEA-1416: a potent systemically active NMDA receptor glycine site antagonist. Eur. J. Pharmacol., 1996, 310(2-3), 107-114.
139. Ohtani, K.; Tanaka, H.; Yasuda, H.; Maruoka, Y.; Kawabe, A.; Nakamura, M. Blocking the glycine-binding site of NMDA receptors prevents the progression of ischemic pathology induced by bilateral carotid artery occlusion in spontaneously hypertensive rats. Brain Res., 2000, 871(2), 311-318.
140. Laube, B.; Hirai, H.; Sturgess, M.; Betz, H.; Kuhse, J. Molecular determinants of agonist discrimination by NMDA receptor subunits: analysis of the glutamate binding site on the NR2B subunit. Neuron, 1997, 18(3), 493-503.
141. Tikhonova, I.G.; Baskin, II; Palyulin, V.A.; Zefirov, N.S. CoMFA and homology-based models of the glycine binding site of Nmethyl-d-aspartate receptor. J. Med. Chem., 2003, 46(9), 1609-1616.
142. Foucaud, B.; Laube, B.; Schemm, R.; Kreimeyer, A.; Goeldner, M.; Betz, H. Structural model of the N-methyl-D-aspartate receptor glycine site probed by site-directed chemical coupling. J. Biol. Chem., 2003, 278(26), 24011-24017.
143. Bacilieri, M.; Varano, F.; Deflorian, F.; Marini, M.; Catarzi, D.; Colotta, V.; Filacchioni, G.; Galli, A.; Costagli, C.; Kaseda, C.; Moro, S. Tandem 3D-QSARs approach as a valuable tool to predict binding affinity data: design of new Gly/NMDA receptor antagonists as a key study. J. Chem. Inf. Mod., 2007, 47(5), 1913-1922.
144. Krueger, B.A.; Weil, T.; Schneider, G. Comparative virtual screening and novelty detection for NMDA-Glycine(B) antagonists. J. Comput. Aided Mol. Des., 2009, 23(12), 869-881.
145. Nikam, S.S.; Meltzer, L.T. NR2B selective NMDA receptor antagonists. Curr. Pharm. Des., 2002, 8(10), 845-855.
146. Borza, I.; Domany, G. NR2B selective NMDA antagonists: the evolution of the ifenprodil-type pharmacophore. Curr. Top. Med. Chem., 2006, 6(7), 687-695.
147. Perin-Dureau, F.; Rachline, J.; Neyton, J.; Paoletti, P. Mapping the binding site of the neuroprotectant ifenprodil on NMDA receptors. J. Neurosci., 2002, 22(14), 5955-5965.
148. Marinelli, L.; Cosconati, S.; Steinbrecher, T.; Limongelli, V.; Bertamino, A.; Novellino, E.; Case, D.A. Homology modeling of NR2B modulatory domain of NMDA receptor and analysis of ifenprodil binding. Chem. Med. Chem., 2007, 2 (10), 1498-1510.
149. Gitto, R.; De Luca, L.; Ferro, S.; Citraro, R.; De Sarro, G.; Costa, L.; Ciranna, L.; Chimirri, A. Development of 3-substituted-1Hindole derivatives as NR2B/NMDA receptor antagonists. Bioorg. Med. Chem., 2009, 17(4), 1640-1647.
150. Borza, I.; Kolok, S.; Gere, A.; Nagy, J.; Fodor, L.; Galgoczy, K.; Fetter, J.; Bertha, F.; Agai, B.; Horvath, C.; Farkas, S.; Domany, G. Benzimidazole-2-carboxamides as novel NR2B selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett., 2006, 16(17), 4638-4640.
151. Borza, I.; Bozo, E.; Barta-Szalai, G.; Kiss, C.; Tarkanyi, G.; Demeter, A.; Gati, T.; Hada, V.; Kolok, S.; Gere, A.; Fodor, L.; Nagy, J.; Galgoczy, K.; Magdo, I.; Agai, B.; Fetter, J.; Bertha, F.; Keseru, G.M.; Horvath, C.; Farkas, S.; Greiner, I.; Domany, G. Selective NR1/2B N-methyl-D-aspartate receptor antagonists among indole-2-carboxamides and benzimidazole-2-carboxamides. J. Med. Chem., 2007, 50(5), 901-914.
152. McCauley, J.A.; Theberge, C.R.; Romano, J.J.; Billings, S.B.; Anderson, K.D.; Claremon, D.A.; Freidinger, R.M.; Bednar, R.A.; Mosser, S.D.; Gaul, S.L.; Connolly, T.M.; Condra, C.L.; Xia, M.; Cunningham, M.E.; Bednar, B.; Stump, G.L.; Lynch, J.J.; Macaulay, A.; Wafford, K.A.; Koblan, K.S.; Liverton, N.J. NR2Bselective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J. Med. Chem., 2004, 47(8), 2089-2096.
153. Buttelmann, B.; Alanine, A.; Bourson, A.; Gill, R.; Heitz, M.P.; Mutel, V.; Pinard, E.; Trube, G.; Wyler, R. 2-(3,4-Dihydro-1Hisoquinolin-2yl)-pyridines as a novel class of NR1/2B subtype selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett., 2003, 13(5), 829-832.
154. Nguyen, K.T.; Claiborne, C.F.; McCauley, J.A.; Libby, B.E.; Claremon, D.A.; Bednar, R.A.; Mosser, S.D.; Gaul, S.L.; Connolly, T.M.; Condra, C.L.; Bednar, B.; Stump, G.L.; Lynch, J.J.; Koblan, K.S.; Liverton, N.J. Cyclic benzamidines as orally efficacious NR2B-selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett., 2007, 17, (14), 3997-4000.
155. Claiborne, C.F.; McCauley, J.A.; Libby, B.E.; Curtis, N.R.; Diggle, H.J.; Kulagowski, J.J.; Michelson, S.R.; Anderson, K.D.; Claremon, D.A.; Freidinger, R.M.; Bednar, R.A.; Mosser, S.D.; Gaul, S.L.; Connolly, T.M.; Condra, C.L.; Bednar, B.; Stump, G.L.; Lynch, J.J.; Macaulay, A.; Wafford, K.A.; Koblan, K.S.; Liverton, N.J. Orally efficacious NR2B-selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett., 2003, 13(4), 697-700.
156. Tewes, B.; Frehland, B.; Schepmann, D.; Schmidtke, K.U.; Winckler, T.; Wunsch, B. Conformationally constrained NR2B selective NMDA receptor antagonists derived from ifenprodil: Synthesis and biological evaluation of tetrahydro-3-benzazepine-1,7-diols. Bioorg. Med. Chem., 2010, 18(22), 8005-8015.
157. Tewes, B.; Frehland, B.; Schepmann, D.; Schmidtke, K.U.; Winckler, T.; Wunsch, B. Design, Synthesis, and Biological Evaluation of 3-Benzazepin-1-ols as NR2B-Selective NMDA Receptor Antagonists. Chem. Med. Chem., 2010, 5(5), 687-695.
158. Mony, L.; Triballeau, N.; Paoletti, P.; Acher, F.C.; Bertrand, H.O. Identification of a novel NR2B-selective NMDA receptor antagonist using a virtual screening approach. Bioorg. Med. Chem. Lett., 2010, 20(18), 5552-5558.
159. Guzikowski, A.P.; Tamiz, A.P.; Acosta-Burruel, M.; Hong-Bae, S.; Cai, S.X.; Hawkinson, J.E.; Keana, J.F.; Kesten, S.R.; Shipp, C.T.; Tran, M.; Whittemore, E.R.; Woodward, R.M.; Wright, J.L.; Zhou, Z.L. Synthesis of N-substituted 4-(4-hydroxyphenyl)piperidines, 4-(4-hydroxybenzyl)piperidines, and (+/-)-3-(4-hydroxyphenyl)pyrrolidines: selective antagonists at the 1A/2B NMDA receptor subtype. J. Med. Chem., 2000, 43(5), 984-994.
160. Gill, R.; Alanine, A.; Bourson, A.; Buttelmann, B.; Fischer, G.; Heitz, M.P.; Kew, J.N.; Levet-Trafit, B.; Lorez, H.P.; Malherbe, P.; Miss, M.T.; Mutel, V.; Pinard, E.; Roever, S.; Schmitt, M.; Trube, G.; Wybrecht, R.; Wyler, R.; Kemp, J.A. Pharmacological characterization of Ro 63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a novel subtype-selective Nmethyl-D-aspartate antagonist. J. Pharmacol. Exp. Ther., 2002, 302(3), 940-948.
161. Pinard, E.; Alanine, A.; Bourson, A.; Buttelmann, B.; Gill, R.; Heitz, M.; Jaeschke, G.; Mutel, V.; Trube, G.; Wyler, R. Discovery of (R)-1-[2-hydroxy-3-(4-hydroxy-phenyl)-propyl]-4-(4-methylbenzyl)-piperidi n-4-ol: a novel NR1/2B subtype selective NMDA receptor antagonist. Bioorg. Med. Chem. Lett., 2001, 11, (16), 2173-2176.
162. Buttelmann, B.; Alanine, A.; Bourson, A.; Gill, R.; Heitz, M.P.; Mutel, V.; Pinard, E.; Trube, G.; Wyler, R. 4-(3,4-dihydro-1Hisoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett., 2003, 13(10), 1759-1762.
163. Malherbe, P.; Mutel, V.; Broger, C.; Perin-Dureau, F.; Kemp, J.A.; Neyton, J.; Paoletti, P.; Kew, J.N. Identification of critical residues in the amino terminal domain of the human NR2B subunit involved in the RO 25-6981 binding pocket. J. Pharmacol. Exp. Ther., 2003, 307(3), 897-905.
164. Mony, L.; Krzaczkowski, L.; Leonetti, M.; Le Goff, A.; Alarcon, K.; Neyton, J.; Bertrand, H.O.; Acher, F.; Paoletti, P. Structural basis of NR2B-selective antagonist recognition by N-methyl-Daspartate receptors. Mol. Pharmacol., 2009, 75(1), 60-74.
165. Ng, F.M.; Geballe, M.T.; Snyder, J.P.; Traynelis, S.F.; Low, C.M. Structural insights into phenylethanolamines high-affinity binding site in NR2B from binding and molecular modeling studies. Molecular Brain, 2008, 1, 16.
166. Gitto, R.; De Luca, L.; Ferro, S.; Occhiuto, F.; Samperi, S.; De Sarro, G.; Russo, E.; Ciranna, L.; Costa, L.; Chimirri, A. Computational studies to discover a new NR2B/NMDA receptor antagonist and evaluation of pharmacological profile. Chem.Med.Chem., 2008, 3(10), 1539-1548.
167. Chimirri, A.; De Luca, L.; Ferro, S.; De Sarro, G.; Ciranna, L.; Gitto, R. Combined strategies for the discovery of ionotropic glutamate receptor antagonists. Chem.Med.Chem., 2009, 4(6), 917-922.
168. Schurr, A. Neuroprotection against ischemic/hypoxic brain damage: blockers of ionotropic glutamate receptor and voltage sensitive calcium channels. Curr. Drug Targets, 2004, 5(7), 603-618.
169. Rogawski, M.A.; Wenk, G.L. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev., 2003, 9(3), 275-308.
170. Sheng, Z.; Prorok, M.; Castellino, F.J. Specific determinants of conantokins that dictate their selectivity for the NR2B subunit of N-methyl-D-aspartate receptors. Neuroscience, 2010, 170(3), 703-710.
171. Sheng, Z.; Liang, Z.; Geiger, J.H.; Prorok, M.; Castellino, F.J. The selectivity of conantokin-G for ion channel inhibition of NR2B subunit-containing NMDA receptors is regulated by amino acid residues in the S2 region of NR2B. Neuropharmacology, 2009, 57(2), 127-136.
172. Alex, A.B.; Saunders, G.W.; Dalpe-Charron, A.; Reilly, C.A.; Wilcox, K.S. CGX-1007 prevents excitotoxic cell death via actions at multiple types of NMDA receptors. Neurotoxicology, 2011, 32(4), 392-399.
173. Wojtal, K.; Borowicz, K.K.; Blaszczyk, B.; Czuczwar, S.J. Interactions of excitatory amino acid receptor antagonists with antiepileptic drugs in three basic models of experimental epilepsy. Pharmacol. Rep., 2006, 58(5), 587-598.
174. Bruno, V.; Battaglia, G.; Copani, A.; D'Onofrio, M.; Di Iorio, P.; De Blasi, A.; Melchiorri, D.; Flor, P.J.; Nicoletti, F. Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs. J. Cereb. Blood Flow Metab., 2001, 21(9), 1013-1033.
175. Borowicz, K.K.; Luszczki, J.J.; Czuczwar, S.J. 2-Methyl-6-phenylethynyl-pyridine (MPEP), a non-competitive mGluR5 antagonist, differentially affects the anticonvulsant activity of four conventional antiepileptic drugs against amygdala-kindled seizures in rats. Pharmacol. Rep., 2009, 61(4), 621-630.
176. Bruno, V.; Ksiazek, I.; Battaglia, G.; Lukic, S.; Leonhardt, T.; Sauer, D.; Gasparini, F.; Kuhn, R.; Nicoletti, F.; Flor, P.J. Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective. Neuropharmacology, 2000, 39(12), 2223-2230.
177. Lea, P.M.T.; Faden, A.I. Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP. CNS Drug Rev., 2006, 12(2), 149-166.
178. Moldrich, R.X.; Chapman, A.G.; De Sarro, G.; Meldrum, B.S. Glutamate metabotropic receptors as targets for drug therapy in epilepsy. Eur. J. Pharmacol., 2003, 476(1-2), 3-16.
179. Alexander, G.M.; Godwin, D.W. Metabotropic glutamate receptors as a strategic target for the treatment of epilepsy. Epilepsy Res., 2006, 71(1), 1-22.
180. Hauser, W.A. Epidemiology of epilepsy in children. Neurosurg. Clin. N. Am., 1995, 6(3), 419-429.
181. Mares, P.; Mikulecka, A.; Ticha, K.; Lojkova-Janeckova, D.; Kubova, H. Metabotropic glutamate receptors as a target for anticonvulsant and anxiolytic action in immature rats. Epilepsia, 2010, 51 Suppl 3, 24-26.
182. Lojkova-Janeckova, D.; Ng, J.; Mares, P. Antagonists of group I metabotropic glutamate receptors and cortical afterdischarges in immature rats. Epilepsia, 2009, 50, (9), 2123-2129.
183. Lopez-Bendito, G.; Shigemoto, R.; Fairen, A.; Lujan, R. Differential distribution of group I metabotropic glutamate receptors during rat cortical development. Cereb. Cortex, 2002, 12(6), 625-638.
184. Lopez-Bendito, G.; Shigemoto, R.; Kulik, A.; Paulsen, O.; Fairen, A.; Lujan, R. Expression and distribution of metabotropic GABA receptor subtypes GABABR1 and GABABR2 during rat neocortical development. Eur. J. Neurosci., 2002, 15(11), 1766-1778.
185. Yasuhara, A.; Chaki, S. Metabotropic glutamate receptors: potential drug targets for psychiatric disorders. Open Med. Chem. J., 2010, 4, 20-36.
186. Monn, J.A.; Valli, M.J.; Massey, S.M.; Wright, R.A.; Salhoff, C.R.; Johnson, B.G.; Howe, T.; Alt, C.A.; Rhodes, G.A.; Robey, R.L.; Griffey, K.R.; Tizzano, J.P.; Kallman, M.J.; Helton, D.R.; Schoepp, D.D. Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J. Med. Chem., 1997, 40(4), 528-537.
187. Schoepp, D.D.; Johnson, B.G.; Wright, R.A.; Salhoff, C.R.; Mayne, N.G.; Wu, S.; Cockerman, S.L.; Burnett, J.P.; Belegaje, R.; Bleakman, D.; Monn, J.A. LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors. Neuropharmacology, 1997, 36(1), 1-11.
188. Bond, A.; Monn, J.A.; Lodge, D. A novel orally active group 2 metabotropic glutamate receptor agonist: LY354740. Neuroreport., 1997, 8(6), 1463-1466.
189. Monn, J.A.; Valli, M.J.; Massey, S.M.; Hansen, M.M.; Kress, T.J.; Wepsiec, J.P.; Harkness, A.R.; Grutsch, J.L., Jr.; Wright, R.A.; Johnson, B.G.; Andis, S.L.; Kingston, A.; Tomlinson, R.; Lewis, R.; Griffey, K.R.; Tizzano, J.P.; Schoepp, D.D. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. J. Med. Chem., 1999, 42(6), 1027-1040.
190. Bond, A.; Ragumoorthy, N.; Monn, J.A.; Hicks, C.A.; Ward, M.A.; Lodge, D.; O'Neill, M.J. LY379268, a potent and selective Group II metabotropic glutamate receptor agonist, is neuroprotective in gerbil global, but not focal, cerebral ischaemia. Neurosci. Lett., 1999, 273(3), 191-194.
191. Nakazato, A.; Kumagai, T.; Sakagami, K.; Yoshikawa, R.; Suzuki, Y.; Chaki, S.; Ito, H.; Taguchi, T.; Nakanishi, S.; Okuyama, S. Synthesis, SARs, and pharmacological characterization of 2-amino-3 or 6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent, selective, and orally active group II metabotropic glutamate receptor agonists. J. Med. Chem., 2000, 43(25), 4893-4909.
192. Klodzinska, A.; Bijak, M.; Chojnacka-Wojcik, E.; Kroczka, B.; Swiader, M.; Czuczwar, S.J.; Pilc, A. Roles of group II metabotropic glutamate receptors in modulation of seizure activity. Naunyn Schmiedebergs Arch. Pharmacol., 2000, 361(3), 283-288.
193. De Sarro, G.; Chimirri, A.; Meldrum, B.S. Group III mGlu receptor agonists potentiate the anticonvulsant effect of AMPA and NMDA receptor block. Eur. J. Pharmacol., 2002, 451(1), 55-61.
194. Borowicz, K.K. Effect of three glutamatergic metabotropic receptor ligands on electrically-induced seizures in mice. J. Pre-Clinical Clinical Res., 2007, 1(1), 47-48.